Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics Acquisition

📆 31/10/2023 08:30:00
📰 SaltWire Network

⏱ Reading Time:
18 sec. here
11 min. at publisher
📊 Quality Score:
News: 41%
Publisher: 63%

Business Notícia

Amgen,Horizon Therapeutics,Acquisition

Amgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.

Watch on - Amgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.

Wall Street analysts, on average, have forecast 2023 earnings of $18.47 per share on revenue of $28 billion, according to LSEG data. Investors will be keen to see whether Amgen, which has operations around the world, can help boost sales of Horizon's two key products, thyroid eye disease treatment Tepezza and gout drug Krystexxa.

Escrever Comentário

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

London stocks rise on strong earning reports; BoE decision in focusMarket News
Fonte: KitcoNewsNOW - 🏆 13. / 78 Consulte Mais informação »